Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. RESULTS: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P<0.001 for both comparisons). Continuous lenalidomide-dexamethasone was superior to MPT for all secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 years was 59% with continuous lenalidomide-dexamethasone, 56% with 18 cycles of lenalidomide-dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with continuous lenalidomide-dexamethasone than with MPT (70% vs. 78%). As compared with MPT, continuous lenalidomide-dexamethasone was associated with fewer hematologic and neurologic toxic events, a moderate increase in infections, and fewer second primary hematologic cancers. CONCLUSIONS: As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation. (Funded by Intergroupe, Francophone du Myélome and Celgene; FIRST ClinicalTrials.gov number, NCT00689936; European Union Drug Regulating Authorities Clinical Trials number, 2007-004823-39.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“However, the incidence of grade 3 or 4 infections was 29% with lenalidomide and dexamethasone in the primary analysis of the FIRST trial,5 which was consistent with the incidence in our trial (32.1% in the daratumumab group and 23.3% in the control group).”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“In this subset of patients, maintenance therapy with proteasome inhibitors alone or in combination with lenalidomide seems to be more effective than single-agent lenalidomide34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“Patients with high-risk cytogenetic features might be the only exception, although they do derive a progression-free survival (PFS) benefit34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“The most worrisome adverse effect observed in studies of lenalidomide maintenance therapy is an up to six-fold increase in the risk of second primary malignancies, in particular, MDS and acute myeloid leukaemia (AML): 5.3% versus 0.8% with placebo or observation34.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Self-citationBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationGroup sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Cited by
Items 401–500 of 793
Ramasamy, K., Dhanasiri, S., Thom, H. H. Z., Buchanan, V., Robinson, S. K., D’Souza, V., & Weisel, K. C. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1683736 · Cited by 11
“In addition to these findings, our NMA suggests that RVd offers OS and PFS benefits over VMP and also the older regimens, MP and MPT, which are no longer recommended by the NCCN V R based on the FIRST trial data [2].”
Self-citationGebauer, N., Biersack, H., Czerwinska, A.-C., Schemme, J., Hardel, T. T., Bernard, V., Rades, D., Lehnert, H., Luley, K. B., & Thorns, C. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1046863 · Cited by 11
Mai, E. K., Miah, K., Bertsch, U., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Munder, M., Lindemann, H., Merz, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0976-9 · Cited by 11
Self-citationShibayama, H., Itagaki, M., Handa, H., Yokoyama, A., Saito, A., Kosugi, S., Ota, S., Yoshimitsu, M., Tanaka, Y., Kurahashi, S., et al. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03754-8 · Cited by 12
“Based on the pivotal phase 3 VISTA [2] and FIRST [3] trials, bortezomib and lenalidomide were further approved for the treatment of newly diagnosed multiple myeloma (NDMM) in 2011 and 2015, respectively.”
MethodHasanali, Z. S., Garfall, A. L., Burzenski, L. M., Shultz, L. D., Tang, Y. J., Kadu, S., Sheppard, N. C., Liu, W., Dopkin, D., Vogl, D. T., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.177300 · Cited by 13
Paul, B. A., Anwer, F., Raza, S., Mammadzadeh, A., Khasawneh, B., Shatnawi, S., McGuirk, J. P., Ahmed, N., Mahmoudjafari, Z., Mushtaq, M. U., et al. (2024) · Cancers · doi:10.3390/cancers16172938 · Cited by 11
“Eventually, the FIRST trial established the superiority of lenalidomide and dexamethasone (Rd) over melphalan, prednisone, and thalidomide (MPT) [30].”
BackgroundJung, S., Koh, Y., Kim, M. K., Kim, J. S., Moon, J., Min, C., Yoon, D. H., Yoon, S. S., Lee, J., Hong, C. M., et al. (2025) · Blood Research · doi:10.1007/s44313-025-00055-9 · Cited by 15
“The FIRST study was an open-label, three-arm phase 3 randomized controlled trial conducted across 246 treatment centers in 18 countries, across Europe, North America, and the Asia–Pacific region [16].”
Self-citationBonello, F., Pulini, S., Ballanti, S., Gentile, M., Spada, S., Annibali, O., Omedè, P., Ronconi, S., Cangialosi, C., Podda, L., et al. (2019) · Cancers · doi:10.3390/cancers11111735 · Cited by 11
Djebbari, F., Rampotas, A., Panitsas, F. P., Lim, W. Y., Lees, C., Tsagkaraki, I., Gomes, A. R., Prideaux, S., Chen, L., Prodger, C. F., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262388 · Cited by 10
“The myeloma treatment landscape for TNE NDMM patients is shifting towards the continuous therapy (CT) strategy, such as continuous lenalidomide and dexamethasone as per FIRST trial [11], continuous daratumumab with lenalidomide and dexamethasone as per MAIA trial [12], and continuous daratumumab with bortezomib, melph…”
MethodRusso, C. D., & Navarra, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.858354 · Cited by 11
Richardson, P. G. G., Mateos, M., Vangsted, A. J., Ramasamy, K., Abildgaard, N., Ho, P. J., Quach, H., & Bahlis, N. J. (2022) · Expert Review of Proteomics · doi:10.1080/14789450.2022.2142564 · Cited by 13
Self-citationde la Rubia, J., Cejalvo, M. J., & Ribas, P. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1088647 · Cited by 11
“Finally, in 2014 the largest randomized, phase III study in transplant-ineligible patients with MM (FIRST trial) was published [34].”
BackgroundMunker, R., Shi, R., Nair, B. S., Devarakonda, S. S., Cotelingam, J. D., McLarty, J. W., Mills, G. M., & Glass, J. (2015) · Acta Haematologica · doi:10.1159/000440970 · Cited by 12
Is it possible to cure myeloma without allogeneic transplantation?
Katodritou, E., Papadaki, S., Konstantinidou, P., & Terpos, E. (2016) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2016.01.015 · Cited by 10
Leleu, X. P., Terpos, E., García‐Sánz, R., Cooney, J. P., O’Gorman, P., Minařík, J., Greil, R., Williams, C. D., Gray, D., & Szabó, Z. R. (2016) · American Journal of Hematology · doi:10.1002/ajh.24416 · Cited by 11
“Our observations confirm the neutropenia rates reported in the European/Australian [8] and North American [9] phase 3 trials of lenalidomide and dexamethasone, as well as a recent phase 3 study [6].”
BackgroundResultWang, H., Xin Min, Z. H. O. U., Zhu, J., Ye, J., Guo, H., & Sun, C. (2018) · Oncology Letters · doi:10.3892/ol.2018.9365 · Cited by 10
“Treatment with lenalidomide provides an alternative choice for elderly patients and those unable to tolerate chemotherapy (16,17).”
Takamatsu, H., Iida, S., Shibayama, H., Shibayama, K., Yamazaki, H., & Suzuki, K. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02825-w · Cited by 10
Bachmann, F., Schreder, M., Engelhardt, M. M., Langer, C., Wolleschak, D., Muegge, L. O., Dürk, H., Schäfer‐Eckart, K., Blau, I. W., Gramatzki, M., et al. (2021) · Cancers · doi:10.3390/cancers13061322 · Cited by 10
“In contrast to a phase 3 study for nontransplant-eligible subjects [15], most recent trials involving high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) applied strict criteria for renal function.”
ResultKobayashi, T., Miura, M., Niioka, T., Abumiya, M., Ito, F., Kobayashi, I., Ikeda, S., Yoshioka, T., Kameoka, Y., & Takahashi, N. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000499 · Cited by 10
How I Manage Frontline Transplant-Ineligible Multiple Myeloma
Derudas, D., Capraro, F., Martinelli, G., & Cerchione, C. (2020) · Hematology Reports · doi:10.4081/hr.2020.8956 · Cited by 11
“cRd vs Rd18 73 (44-91) vs 73 (40-89) 75 vs 73 vs 62 85 vs 80 vs 89 25,5 vs 20,7 (HR 0,7; 4 years OS: 59% vs vs MPT (n=1623) vs 73 (51-92) y p < 0,001) vs 21,2 56% (HR 0,9; p =0,31) (HR 0,72; p > 0,001) vs 51% (HR 0,78;”
Nakaya, A., Fujita, S., Satake, A., Nakanishi, T., Azuma, Y., Tsubokura, Y., Hotta, M., Yoshimura, H., Ishii, K., Ito, T., et al. (2017) · Acta Haematologica · doi:10.1159/000477792 · Cited by 10
First linevsdelayed transplantation in myeloma: Certainties and controversies
Brioli, A. (2016) · World Journal of Transplantation · doi:10.5500/wjt.v6.i2.321 · Cited by 11
Fresh perspectives on treatment and moments of clarity
Kapoor, P., & Rajkumar, S. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.221 · Cited by 9
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
Cerrato, C., Raimondo, F. D., Paoli, L. D., Spada, S., Patriarca, F. F., Crippa, C., Mina, R., Guglielmelli, T., Ben‐Yehuda, D., Oddolo, D., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2641-5 · Cited by 10
“In patients ineligible for ASCT, continuous therapy with lenalidomide and dexamethasone improved PFS and overall survival (OS) as compared with MPT (Benboubker et al. 2014).”
InfluentialMultiple myeloma – 2020 update on diagnosis and management
Charliński, G., & Jurczyszyn, A. J. (2020) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2020.0035 · Cited by 10
“The two following options are recommended based on data from randomised phase III trials: VMP (bortezomib administered subcutaneously) [39] or Rd [40]; both VMP and Rd are approved in this setting by the European Medicines Agency (EMA).”
BackgroundCao, Y., Zhao, L., Zhang, T., & Cao, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.608685 · Cited by 9
Qian, X., Yang, Y., Deng, Y., Liu, Y., Zhou, Y., Han, F., Xu, Y., & Yuan, H. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11973 · Cited by 10
Richardson, P. G., Durie, B. G., Rosiñol, L., Mateos, M.-V., Dispenzieri, A., Moreau, P., Kumar, S., Raje, N., Munshi, N., Laubach, J. P., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282624 · Cited by 9
“Of note, those who received RVd for induction had an ORR of 89% compared to 75% in those who received salvage, with no cases of grade ≥ 3 PN.”
BackgroundInfluentialSelf-citationAn update on the use of lenalidomide for the treatment of multiple myeloma
Zagouri, F., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1067681 · Cited by 11
Self-citationMultiple myeloma: is a shift toward continuous therapy needed to move forward?
Guglielmelli, T., & Palumbo, A. P. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1001360 · Cited by 9
“The role of lenalidomide maintenance was also confirmed in the recently published FIRST study [12].”
BackgroundKibata, K., Ito, T., Inaba, M., Tanaka, A., Iwata, R., Inagaki‐Katashiba, N., Phan, V. T. X., Satake, A., & Nomura, S. (2019) · Journal of Blood Medicine · doi:10.2147/jbm.s206459 · Cited by 11
“Continuous treatment with LEN until diseases progression confers a survival benefit for MM patients.(1)”
BackgroundMaintenance therapy and need for cessation studies in multiple myeloma: Focus on the future
Diamond, B. T., Maclachlan, K. H., Chung, D. J., Lesokhin, A. M., & Landgren, O. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101140 · Cited by 9
Modern treatments and future directions for newly diagnosed multiple myeloma patients
Lu, S. X. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101151 · Cited by 11
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., Frank, M. J., Weng, W., Lowsky, R., Rezvani, A. R., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.02.026 · Cited by 9
Gutowska, A., McKinnon, K. M., Sarkis, S., Doster, M. N., Bissa, M., Moles, R., Stamos, J. D., Rahman, M. A., Washington‐Parks, R., Davis, D. A., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.897264 · Cited by 13
“Indeed, lenalidomide plus low-dose dexamethasone until progression is the standard of care for newly diagnosed multiple myeloma patients (53, 54).”
BackgroundNewly diagnosed multiple myeloma: making sense of the menu
Costello, C. L. (2022) · Hematology · doi:10.1182/hematology.2022000404 · Cited by 12
Oertel, M., Schlusemann, T., Shumilov, E., Reinartz, G., Bremer, A., Rehn, S., Lenz, G., Khandanpour, C., & Eich, H. T. (2023) · Cancers · doi:10.3390/cancers15112909 · Cited by 12
Should minimal residual disease negativity be the end point of myeloma therapy?
Anderson, K. C. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016000117 · Cited by 12
Self-citationDote, S., Ito, K., Itakura, S., Yasu, T., Hira, D., Noda, S., Yamada, S., Kobayashi, Y., & Terada, T. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1608531 · Cited by 9
Li, S., Zhang, D., Yang, L., Huang, C., Niu, T., & Gong, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.5422 · Cited by 7
Sequencing of nontransplant treatments in multiple myeloma patients with active disease
Yee, A. J., & Raje, N. S. (2016) · Hematology · doi:10.1182/asheducation-2016.1.495 · Cited by 8
Grant, S. J., & Lipe, B. C. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(20)30470-5 · Cited by 9
Tang, W., Li, Y., Zou, Z., Cui, J., Wang, F., Zheng, Y., Hou, L., Pan, L., Xiang, B., Chang, H., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5228 · Cited by 10
Côté, J. A., Kotb, R. R., Bergstrom, D. J., LeBlanc, R., Mian, H. S., Othman, I., & Louzada, M. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.01.016 · Cited by 10
Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
Solimando, A. G., Krebs, M., Desantis, V., Marziliano, D., Caradonna, I. C., Morizio, A., Argentiero, A., Shahini, E., & Bittrich, M. (2023) · Biomedicines · doi:10.3390/biomedicines11072087 · Cited by 13
“An OS advantage was also demonstrated for patients in the continuous Rd arm when compared to patients in the MPT arm (HR: 0.78; CI, 0.64–0.96, p = 0.02) [116].”
ResultInfluentialFabro, V. D., Giorgio, M. A. D., Leotta, V., Duminuco, A., Bellofiore, C., Markovic, U., Romano, A., Bulla, A., Pelle, A. C., Elia, F., et al. (2023) · Cancers · doi:10.3390/cancers15164036 · Cited by 9
“Since its approval following the FIRST trial results, Len/Dex combination therapy has represented a valid therapeutic alternative in a population of often particularly fragile patients such as n t-transplant-eligible patients.”
BackgroundInfluentialOral ixazomib maintenance therapy in multiple myeloma
Offidani, M., Corvatta, L., Gentili, S., Maracci, L., & Leoni, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1123627 · Cited by 9
“[31] The recently published FIRST trial [32,33] including 1623 elderly patients randomly assigned to continuous lenalidomide plus dexamethasone (Rd), 18 cycles of Rd or 12 cycles of MPT, showed the superiority of continuous Rd over the other two arms in terms of PFS and an OS benefit with continuous treatment if compa…”
BackgroundMethodInfluentialHarousseau, J., & Mohty, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-18218-6 · Cited by 9
Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
Lee, H. S., & Min, C. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.110 · Cited by 11
“The clinical outcomes of maintenance therapy for patients with transplant-ineligible MM are summarized in Table 3 [39-51].”
BackgroundThromboprophylaxis in Multiple Myeloma Patients Treated with Lenalidomide - a Systematic Review
Al‐Ani, F., Louzada, M., Bastida, J. M., & Mateos, M. (2015) · Blood · doi:10.1182/blood.v126.23.2321.2321 · Cited by 9
Rodríguez‐Otero, P., Mateos, M., Martínez‐López, J., Martín‐Calvo, N., Hernández, M.-T., Ocio, E. M., Rosiñol, L., Martínez, R., Teruel, A. I., Gutierrez, N. C., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0072-6 · Cited by 9
Self-citationHari, P., Lin, H. M., Zhu, Y., Berg, D. T., Richardson, P. G. G., & Moreau, P. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1474745 · Cited by 9
Self-citationTriplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities
Paner, A., Okwuosa, T. M., Richardson, K. J., & Libby, E. N. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1538777 · Cited by 8
“In 2015, three randomized phase 3 trials consistently demonstrated improvement in RRs and PFS after a third agent was added to the backbone of Rd in RRMM with 1–3 prior lines of therapy [9,12,13].”
BackgroundInfluentialXu, W., Li, D., Sun, Y., Ran, X., Wang, B., Wu, W., Sheng, Z., & Liu, L. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13317 · Cited by 10
Zamagni, E., Dhanasiri, S., Ghale, A., Moore, A., & Roussel, M. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1924369 · Cited by 8
“The use of these therapies for transplant-ineligible patients has improved clinical outcomes and increased the number of treatment options [4,5,9], but to our knowledge, there are no data that directly compare clinical characteristics, treatment outcomes (e.”
BackgroundRecent advances in the management of older adults with newly diagnosed multiple myeloma in Japan
Suzuki, T., Maruyama, D., Iida, S., & Nagai, H. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac111 · Cited by 9
“Using performance status (PS) instead of ADL and IADL, a simplified frailty score using age, CCI and PS was developed from a supplementary analysis of the FIRST trial (9,10).”
BackgroundResultInfluentialMultiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00101-8 · Cited by 8
Self-citationYin, Q., Chen, L., Mi, R., Ai, H., Yin, J.-J., Liu, X.-J., & Wei, X. (2016) · Medical Science Monitor · doi:10.12659/msm.900575 · Cited by 8
“These drugs have largely improved the rate of complete remission, and significantly increased the time to progression, progression-free survival, and overall survival [4,5].”
BackgroundKim, M. K., Kım, K., Min, C., Kwak, J., Bae, S. B., Yoon, S., Lee, J., Kim, K. H., Nam, S.-H., Mun, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16790 · Cited by 8
“Recently, alkylator-free continuous lenalidomide-dexamethasone (Rd) given until disease progression showed superior PFS and OS to melphalan-prednisone-thalidomide (MPT) in transplantineligible patients with myeloma [20].”
BackgroundSelf-citationIxazomib in the Management of Relapsed Multiple Myeloma
Touzeau, C., & Moreau, P. (2018) · Future Oncology · doi:10.2217/fon-2017-0710 · Cited by 10
Self-citationMechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma
Nooka, A. K., & Lonial, S. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000354 · Cited by 8
The safety of current and emerging therapies for multiple myeloma
Nadeem, O., & Anderson, K. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1733968 · Cited by 8
Self-citationBerdeja, J. G., Bauer, T. M., Arrowsmith, E. R., Essell, J. H., Murphy, P., Reeves, J. A., Boccia, R. V., Donnellan, W. B., & Flinn, I. W. (2017) · British Journal of Haematology · doi:10.1111/bjh.14536 · Cited by 8
Merz, A. M. A., Merz, M., Hillengaß, J., Holstein, S. A., & McCarthy, P. L. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1674142 · Cited by 8
Discovery of novel benzosultam CRBN ligands
Park, H., Raikar, S. S., Kim, Y., Chae, C. H., Cho, Y., & Kim, P. (2025) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12921 · Cited by 7
Mateos, M., Paiva, B., Cedena, M., Puig, N., Sureda, A. M., González‐Calle, V., Oriol, A., Ocio, E. M., Rosiñol, L., Montes, Y. G., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00143-7 · Cited by 11
Self-citationKastritis, E., Ntanasis‐Stathopoulos, I., Theodorakakou, F., Migkou, M., Ρούσσου, Μ., Malandrakis, P., Kanellias, N., Eleutherakis‐Papaiakovou, E., Fotiou, D., Spiliopoulou, V., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.03.003 · Cited by 9
Self-citationPersonalized Treatment of Multiple Myeloma in Frail Patients
Lipof, J. J., Abdallah, N. H., & Lipe, B. C. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01545-2 · Cited by 10
“Historically, this has been the combination of lenalidomide and dexamethasone, which led to an improvement in PFS when compared to MPT (melphalan, prednisone, and thalidomide) (HR, 0.70; 95% CI 0.60–0.82; p < 0.001) [57].”
InfluentialYong, K., Einsele, H., Schecter, J. M., Roccia, T., Deraedt, W. M., Lendvai, N. K., Slaughter, A., Lonardi, C., Connors, K., Qi, K., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115157 · Cited by 7
Dimopoulos, M. A., Cavo, M., Mateos, M., Facon, T. T. F., Heeg, B. M. S., van Beekhuizen, S., Gebregergish, S. B., Nair, S. C., Pisini, M., Lam, A., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1682571 · Cited by 7
“Baseline patient characteristics from FIRST (NCT00689936) were obtained from published literature [4].”
BackgroundMethodSelf-citationRosenberg, A. S., Facon, T. T. F., Parikh, K., Chung, W., Srinivasan, S. S., Kotey, S., & Tuscano, J. M. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.12.021 · Cited by 7
Self-citationSugi, T., Mita, M., Yasu, T., Ohara, S., Uchida, T., Inoue, M., & Hagihara, M. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13433 · Cited by 7
Rafae, A., Ehsan, H., Wahab, A., Khan, S. I., KHAN, I. A., Ashraf, S., Ali, S., Khalid, F., Neupane, K., Valent, J. N., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103744 · Cited by 7
Timing of treatment of smoldering myeloma: delay until progression
Kumar, S. K. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018021238 · Cited by 7
“Multiple small single-arm trials have demonstrated that the currently used myeloma treatment regimens can be effective against the plasma cells in these patients leading to deep responses, including minimal residual disease–negative state (Table 2).(18-23) But what we really need to see is not only a deep response or…”
BackgroundLenalidomide as maintenance for every newly diagnosed patient with multiple myeloma
Mateos, M., & González‐Calle, V. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30764-2 · Cited by 8
Kobayashi, T., Miura, M., Abumiya, M., Akamine, Y., Ito, F., & Takahashi, N. (2019) · Medical Oncology · doi:10.1007/s12032-019-1280-2 · Cited by 7
Outcomes of lenalidomide‐ or bortezomib‐based regimens in older patients with plasma cell myeloma
Barth, P. M., Giri, S., Reagan, J. L., & Olszewski, A. J. (2020) · American Journal of Hematology · doi:10.1002/ajh.25996 · Cited by 8
“For example, 4-year OS was 59% in the FIRST trial for open-ended RD therapy.(7) In the S0777 trial, median OS with RVD was 6.”
BackgroundOld and new generation immunomodulatory drugs in multiple myeloma
Derudas, D., Capraro, F., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04125-7 · Cited by 8
Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma
Sugi, T., Nishigami, Y., Hirohisa, S., Hanai, H., Keisuke, T., Mita, M., Ohara, S., Ide, S., Uchida, T., Inoue, M., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1876867 · Cited by 8
Mark, T. M., Falkenstein, A., & Kish, J. K. (2021) · Future Oncology · doi:10.2217/fon-2021-1176 · Cited by 8
Major, A., Jakubowiak, A. J., & Derman, B. A. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.07.002 · Cited by 7
New prognostic tools for myeloma
Mellqvist, U. (2015) · Blood · doi:10.1182/blood-2015-02-626408 · Cited by 7
Beijers, T. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20161213tp · Cited by 7
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts
Delforge, M., Vlayen, S., & Kint, N. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1905513 · Cited by 7
“By demonstrating a significantly longer PFS, Rd until progression became the new standard of care for ND NTE MM patients in many parts of the world [87].”
BackgroundSelf-citationManaging multiple myeloma in the over 70s: A review
King, A. J., Gooding, S., & Ramasamy, K. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.11.017 · Cited by 7
Štork, M., SEVCIKOVA, S., Adam, Z., Krejčí, M., Sandecká, V., Král, Z., Brožová, L., Velichová, R., & Pour, L. (2018) · Neoplasma · doi:10.4149/neo_2018_170519n363 · Cited by 6
Milrod, C. J., Blevins, F., Hughes, D., Lerner, A., Sarosiek, S., Sanchorawala, V., & Sloan, J. M. (2021) · Blood · doi:10.1182/blood.2021010853 · Cited by 6
Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma
Ravi, G., & Gonsalves, W. I. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100444 · Cited by 8
“Thus, in these scenarios, doublet-based regimens with either lenalidomide and dexamethasone(71) or even bortezomib and dexamethasone remain reasonable alternatives.”
BackgroundBuda, G., Giudice, M. L. D., Antonioli, E., Ghio, F., Orciuolo, E., Morganti, R., Martini, F., Staderini, M., Galimberti, S., & Petrini, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.712070 · Cited by 6
Examining health related quality of life outcomes in multiple myeloma: Past and future perspectives
Hevroni, G., & Korde, N. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.002 · Cited by 6
Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults
Guerard, E. J., & Tuchman, S. A. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.08.012 · Cited by 7
Jung, S., Choi, H., Shin, M., Lee, S.-S., Hwang, E. C., Jung, T., Cho, M.-S., Yang, D., Ahn, J., Kim, Y., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2743-6 · Cited by 6
Self-citationHigh-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges
Muchtar, E., Magen, H., & Gertz, M. A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1233540 · Cited by 6
“The FIRST trial compared continuous lenalidomide–dexamethasone with lenalidomide–dexamethasone at fixed duration (18 cycles) and with a thalidomide-based regimen (MPT) in transplant ineligible patients.[78] This trial demonstrated that while continuous Rd resulted in improved outcomes in non-high risk cytogenetics com…”
ResultLi, J.-L., Fan, G.-Y., Liu, Y., Zeng, Z., Huang, J., Yang, Z., & Meng, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00430 · Cited by 7
“…mainstay drug, there wasno significant heterogeneity among studies Frontiers in Pharmacology | www.frontiersin.org 7 April 2018 | Volume 9 | Article 430 identified that the study by Benboubker et al. (2014) was the most influential among studies comparing Len-based regimens and controls (I2 = 61%).”
BackgroundInfluentialToxicities of novel therapies for hematologic malignancies
Simon, F., Borrega, J. G., & Bröckelmann, P. J. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1728249 · Cited by 6
“2% of patients; however, no robust data regarding risks and benefits prophylactic anticoagulation in patients treated with lenalidomide exist [82].”
BackgroundTiming of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies
Leng, S., Moshier, E. L., Tremblay, D. A., Hu, L., Biran, N., Barman, N., Parekh, S. S., Cho, H. J., Madduri, D., Richter, J. R., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.05.027 · Cited by 6
Hungria, V., Martinez-Banos, D. M., Mateos, M., Dimopoulos, M. A., Cavo, M., Heeg, B. M. S., Garcia, A. M., Lam, A., Machnicki, G., He, J., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01521-9 · Cited by 6
Self-citationBergin, K., Yuen, F., Wallington-Beddoe, C. T., Kalff, A., Sirdesai, S., Reynolds, J., & Spencer, A. G. (2021) · British Journal of Haematology · doi:10.1111/bjh.17504 · Cited by 6
Nakazato, T., Hagihara, M., Sahara, N., Tamai, Y., Ishii, R., Tamaki, S., Wake, A., Tajika, K., Sakai, R., Kobayashi, T., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04592-y · Cited by 6
Jung, S., Lee, J., Song, G., Lee, H. S., Kim, S. J., Yoon, S. E., & Kım, K. (2021) · British Journal of Haematology · doi:10.1111/bjh.17898 · Cited by 6
“gov Identifier: NCT00689936), which demonstrated the efficacy of lenalidomide and dexamethasone (Rd) regimen for transplantineligible patients with NDMM, was conducted from 2008 to 2011; the results were reported in 2014.(7) However, an Rd regimen for NDMM was approved for use in 2015 and was approved for reimbursemen…”
ResultSelf-citation
Metadata
- Authors
- Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J.-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., & Facon, T.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Mayo Clinic (US)
- Frankston Hospital (AU)
- University of Alberta (CA)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Tübingen (DE)
- Wilhelminen Hospital (AT)
- University of Calgary (CA)
- Centre Hospitalier de la Côte Basque (FR)
- Universitair Ziekenhuis Leuven (BE)
- St Bartholomew's Hospital (GB)
- Unidade Local de Saúde de Coimbra (PT)
- Chonnam National University Hwasun Hospital (KR)
- Princess Margaret Cancer Centre (CA)
- Josep Carreras Leukaemia Research Institute (ES)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Dalhousie University (CA)
- Kantonsspital Winterthur (CH)
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Louis (FR)
- Hôpital Purpan (FR)
- Celgene (United States) (US)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- ORCID
- Benboubker, Lotfi
- Dimopoulos, Meletios A.
- Dispenzieri, Angela
- Belch, Andrew R.
- Weisel, Katja
- Ludwig, Heinz
- Bahlis, Nizar
- Banos, Anne
- Geraldes, Catarina
- Lee, Je-Jung
- Chen, Christine
- Oriol, Albert
- Qiu, Lugui
- White, Darrell J.
- Anderson, Kenneth
- Fermand, Jean-Paul
- Moreau, Philippe
- Attal, Michel
- Knight, Robert
- Chen, Guang
- Jacques, Christian
- Hulin, Cyrille
- Facon, Thierry
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-04
- Volume
- 371
- Issue
- 10
- Pages
- 906-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141105112
- Cited by
- 793
- References
- 38
- Citations by year
- 2026: 18 · 2025: 41 · 2024: 39 · 2023: 37 · 2022: 54 · 2021: 74 · 2020: 89 · 2019: 75 · 2018: 80 · 2017: 92 · 2016: 102 · 2015: 76 · 2014: 15
- FWCI
- 67.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- lenalidomide, dexamethasone, multiple myeloma, transplant-ineligible patients, progression-free survival, overall survival, treatment duration, adverse events, second primary malignancy, infection, neurotoxicity, hematologic toxicity, newly diagnosed multiple myeloma
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prednisone, Thalidomide, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.